Yosemite's second fund targets $350 million amid biotech resurgence
Reed Jobs, founder of oncology-focused venture firm Yosemite, announced the first close of its second fund targeting $350 million in early 2026. The firm, launched in 2023, now employs 17 people and has invested in 20 portfolio companies. Jobs described the current state as one of 'extreme activity,' citing improved interest rates and pharma's largest patent cliff in history as key tailwinds. The patent cliff—where blockbuster drugs lose protection in a concentrated window—has triggered an acquisition spree over the past eight months, with deals like Eli Lilly's $7 billion purchase of Kelonia. Yosemite allocates about one-third of its capital to companies it builds from scratch, often from early academic research, while the rest goes into externally founded startups. A separate 2.5% of fund assets goes into a donor-advised fund for no-strings-attached grants, supplemented by $1 million annually from management fees. Jobs emphasized that Yosemite's unique model combines philanthropy with venture capital to de-risk early-stage ideas, particularly those emerging from university labs at Yale, Berkeley, and Stanford.
AI transforms drug discovery and clinical trial design at Yosemite
Artificial intelligence has moved from a curiosity to a 'huge part' of Yosemite's operations, according to Jobs. The firm leverages AI for both drug discovery and clinical trial design, areas where Jobs sees transformative potential. In drug discovery, AI accelerates what he calls 'grunt work'—tasks like analyzing protein structures or predicting drug-target interactions—democratizing access to advanced computational tools for smaller labs. More critically, AI is reshaping clinical trials, the largest cost and time sink in drug development. A Phase 3 cancer trial costs approximately $260 million, with only one in three succeeding, and patient recruitment and retention represent the biggest expense. AI enables synthetic control arms—computer-generated comparison groups built from existing patient data—which could halve the number of patients needed by eliminating the need for a full control group. The FDA is reportedly leaning into this approach, potentially speeding up trial timelines and reducing costs. Jobs highlighted that American hospitals remain 'technologically naive,' with reliance on fax machines and floppy disks, making healthcare delivery ripe for AI disruption in areas like 911 triage, electronic health records, radiology, and pathology.
Portfolio highlights: Azalea and Quarry lead Yosemite's company-building efforts
Among Yosemite's portfolio, Jobs singled out Azalea and Quarry as standout companies. Azalea originated from a grant to Jennifer Doudna's lab at UC Berkeley and has since entered clinical trials. Quarry, built with serial entrepreneur Craig Crews, focuses on induced proximity—a therapeutic approach where a drug physically drags a disease-causing protein to the cell's breakdown system, rather than blocking it directly. Jobs noted that Yosemite's model of building companies from academic research allows it to create entirely new areas of medicine. The firm pioneered epigenetic gene editing, which modifies gene expression without altering DNA sequence, and safe delivery of gene editing to specific cells—a bottleneck that has stymied the field for nearly a decade. Two of Yosemite's 20 first-fund companies emerged directly from its grant program, which provides no-strings-attached funding to university labs. Jobs emphasized that Yosemite's ability to identify and nurture early-stage ideas before they attract broader venture interest gives it a competitive edge. The firm's academic partnerships span Yale, Berkeley, and Stanford, with plans to expand as the second fund scales.
NIH funding threats persist but bipartisan support holds
Jobs expressed ongoing concern about proposed NIH budget cuts, though he noted the threat has diminished compared to 2025. Last year, an administration requested a 40% cut to the NIH budget—the largest in history, compared to the previous record of 1% in 2009 during the global financial crisis, which cost 7,000 scientists their jobs. The Senate and House, in a rare bipartisan move, rejected the 40% cut. This year, the administration proposed a 12% reduction, still the largest ever by an order of magnitude, but Jobs expects similar rejection given that NIH funding enjoys over 90% approval. He argued that NIH funding has not grown on a dollar basis in roughly a decade, meaning it has effectively shrunk relative to inflation. Jobs advocates going on offense, proposing an increase to $100 billion annually. He linked stable NIH funding to the broader biotech ecosystem, noting that academic research funded by NIH often seeds the startups Yosemite invests in. The political pressure, while reduced, remains a concern for long-term planning in the sector.
Patent cliff triggers pharma acquisition spree, boosting biotech exits
The pharmaceutical industry is entering its largest patent cliff in history, with a cluster of blockbuster drugs losing protection in a concentrated window. Combined with record cash reserves accumulated during the pandemic, this has driven an acquisition spree over the past eight months, according to Jobs. Notable exits include Eli Lilly's $7 billion acquisition of Kelonia and significant wins in antibody drug conjugates. Jobs highlighted Revolution Medicines, which targets the KRAS mutation in pancreatic cancer—one of the most commonly mutated and historically undruggable cancer drivers. The company doubled survival rates for the most common form of pancreatic cancer from 12 to 24 months, a milestone achieved only in the past year. Jobs noted that when he launched Yosemite in 2023, the XBI biotech index was still down from 2021 highs and pharma had not yet become acquisitive. The improved interest rate environment has further supported the rebound. This favorable macro backdrop, combined with Yosemite's focus on oncology—40% of the biotech market—positions the firm to capitalize on the patent cliff opportunity, Jobs said.